Vertex Acquires ViaCyte

Vertex Pharmaceuticals announces that they have acquired ViaCyte to help speed up the development of VX-880, Vertex’s stem cell-derived therapy for people with T1D. This merger brings together two of the biggest companies pursuing cell replacement therapy, and will allow them to combine their resources, technologies, intellectual property, and more.